Enriqueta Felip

Research interests

Publications

• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

  The Lancet · 2023 · 10.1016/s0140-6736(23)00221-0

• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2307980

• Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2112431

• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30641-0

• Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

  The Lancet · 2021 · 10.1016/s0140-6736(21)02098-5

• Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.03136

• Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917346

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30314-4

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002787

• Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2004407

• First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2027187

• Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810171

• Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

  JAMA Oncology · 2018 · 10.1001/jamaoncol.2017.4771

• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30649-1

• Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1801005

• Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.70.3223

• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1613493

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.74.3062

• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30339-x

• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.6601

• Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1501824

• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

  Nature Communications · 2015 · 10.1038/ncomms9839

• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)01281-7

• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1411817

• Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1507643

• Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

  Nature Medicine · 2015 · 10.1038/nm.3854

• Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1311107

• First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1408440

• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2012 · 10.1093/annonc/mds226

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(11)70393-x

Current projects

No projects listed.